Episode 17: Dose Expansion Phases in Oncology Trials episode artwork

EPISODE · Oct 17, 2025 · 13 MIN

Episode 17: Dose Expansion Phases in Oncology Trials

from QCast: Data-Driven Dialogue in Drug Development · host Quanticate

In this QCast episode, Jullia and Tom explore the dose expansion phase of phase one oncology trials — the critical bridge between dose finding and proof of concept. They discuss how expansion cohorts confirm safety, explore early efficacy signals, and refine dose and schedule decisions, along with best practices for design, governance, and regulatory alignment that set the stage for a successful phase two. Key TakeawaysTreat the dose expansion phase as a structured bridge between dose finding and phase two readiness.Define clear objectives, eligibility criteria, and decision rules for each cohort to maintain scientific focus.Align dose and schedule choices with exposure–response evidence and biological rationale.Build flexibility into the protocol through controlled adaptation and version management.Use pragmatic endpoints — safety, tolerability, and early activity — to inform, not confirm, efficacy.Maintain data integrity with cohort tagging, consistent assessments, and audit-ready documentation.Carry forward lessons on dose, population, and endpoints to streamline the next phase of development. 🔗 Learn More & Get Support: Visit quanticate.com to explore our biometrics services and discover how we can support your next clinical trial. 📝 Episode Notes & Transcript: Find show notes, resources, and a full transcript at quanticate.com/podcast.🔔 Stay Connected: Subscribe to QCast on Apple Podcasts, Spotify, or your favourite platform to never miss an episode.About QuanticateFounded in 1994, Quanticate is a biometrics-focused CRO with over 30 years' experience delivering expert clinical and post-marketing data services worldwide. Specialising in the collection, management, standardisation, analysis, and reporting of data, we support pharma and biotech companies globally with high-quality solutions for clinical development. We specialise in:Clinical Data Capture & ManagementBiostatistics & Statistical ConsultancyStatistical Programming & PK/PD AnalysisMedical Writing & PharmacovigilanceRegulatory & Submission SupportAI & AutomationPost-Marketing Safety & Real-World DataQuanticate is committed to delivering expertise and solutions that drive the success of clinical development worldwide.

Episode metadata supplied by the publisher feed · Published Oct 17, 2025

Embed this episode

In this QCast episode, Jullia and Tom explore the dose expansion phase of phase one oncology trials — the critical bridge between dose finding and proof of concept. They discuss how expansion cohorts confirm safety, explore early efficacy signals, and refine dose and schedule decisions, along with best practices for design, governance, and regulatory alignment that set the stage for a successful phase two. Key Takeaways Treat the dose expansion phase as a structured bridge between dose ...

Distinct summary based on available episode metadata or transcript content.

Ready to play

Episode 17: Dose Expansion Phases in Oncology Trials

0:00 13:12

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of QCast: Data-Driven Dialogue in Drug Development?

This episode is 13 minutes long.

When was this QCast: Data-Driven Dialogue in Drug Development episode published?

This episode was published on October 17, 2025.

Can I download this QCast: Data-Driven Dialogue in Drug Development episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!